[Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma].
From January 1990 to November 1994, 23 patients with advanced pretreated lung carcinoma were enrolled into a phase II trial to test a new nitrosourea, cystemustine, given every 2 weeks at the dose of 60 mg/m(2) in a 15-minute IV infusion. All eligible patients were considered evaluable for response and toxicity (WHO criteria).